Back to results
US 6,440,676 B1Granted
Diagnostic assay for cancer
AssigneeNyxis NeuroTherapies, Inc.
InventorsRoger A. Kroes, Joseph R. Moskal, Hirotaka Yamamoto
Life of this patent
Estimating the term…
Abstract
The invention is directed towards gene expression characteristic for cancer, in particular brain cancers such as glioblastoma. Compositions, methods and kits encompassing such therein.
Claims10
A method for determining the effectiveness of a treatment regimen for brain cancer, the method comprising:
- (a) removing a control biological sample from a patient prior to treatment;
- (b) determining the amount of transcription in the control biological sample of a nucleic acid transcript selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, and SEQ ID NO. 9;
- (c) removing a test biological sample from a patient following treatment;
- and
- (d) determining the amount of transcription in the test biological sample of a nucleic acid transcript selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, and SEQ ID NO. 9;
- wherein a decreased amount of transcription in the test sample relative to the control sample indicates that the treatment regimen for brain cancer is effective.
3 more elements
A method for determining the effectiveness of a treatment regimen for breast cancer, the method comprising:
- (a) removing a control biological sample from a patient prior to treatment;
- (b) determining the amount of transcription in the control biological sample of a nucleic acid transcript selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, and SEQ ID NO. 9;
- (c) removing a test biological sample from a patient following treatment;
- and,
- (d) determining the amount of transcription in the test biological sample of a nucleic acid transcript selected from the group consisting of SEQ ID NO. 1, SEQ ID NO. 2, SEQ ID NO. 3, SEQ ID NO. 4, SEQ ID NO. 5, SEQ ID NO. 6, SEQ ID NO. 7, SEQ ID NO. 8, and SEQ ID NO. 9;
- wherein a decreased amount of transcription in the test sample relative to the control sample indicates that the treatment regimen for breast cancer is effective.
3 more elements
Dependencies are inferred from the claim text.